Navigation Links
Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
Date:3/17/2008

WOBURN, Massachusetts, March 17 /PRNewswire/ -- Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has retained Marquant Partners LLC (http://www.marquantpartners.com) to advise on its strategic and partnering opportunities, with the aim of maximizing value for MTI's shareholders.

This appointment follows a significant amount of interest that MTI has attracted from both financial and pharmaceutical companies after its announcement in November 2007 that it had made significant progress in its small molecule AMPK activator development program. Marquant is a specialist life sciences corporate finance boutique focused on advising privately held, small cap and emerging companies on licensing transactions, M&A, divestments, corporate strategy and company formation. Marquant's founders and principals are:

Dr. Pamela Joy Barton has over 12 years experience working with companies in the life sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), IPOs and financings. Prior to Marquant, Joy's positions included: Vice President, Business Development at Nabi Biopharmaceuticals; Vice President, Business Development at Sosei Co. Ltd; Commercial Director at Xenova Group Limited; member of the Pharmaceuticals and Medical Products practice at Accenture; and various roles in the oncology therapeutic area with Novartis/Sandoz.

Dean Brown has over 14 years experience working as a transaction adviser to companies in the Life Sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), and financings. Prior to Marquant, Dean spent almost 11 years as a partner with the Ferghana Partners Group, a boutique transaction advisory house operating in Europe and North America. During thi
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANTONIO , 23 de julio de 2014 ... (ADBI o la Compañía) ha anunciado hoy una ... Akron (ABIA o el Instituto), para ... ADBI, un dispositivo de terapia de señal bioeléctrica ... El Instituto, que tiene una importante ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... producing sustainable chemicals, today announced that the underwriters of ... option to purchase an additional 420,000 shares of ... $12.00 per share, less underwriting discounts and commissions, ... offering of 2,800,000 shares of common stock, bringing ...
(Date:7/23/2014)... MENLO PARK, Calif. , July 23, 2014 /PRNewswire/ ... based investment firm, today announced the closing of Sofinnova ... $500 million and in excess of the initial fund ... on helping entrepreneurs build successful biotechnology companies. Consistent with ... companies with promising later stage clinical programs, along with ...
(Date:7/23/2014)... a2z Inc. announces that AACC will include ... in its 2014 Annual Meeting & Clinical Lab ... for July 29-31, 2014 in Chicago, IL at McCormick ... with global leaders in clinical chemistry, molecular diagnostics, mass ... breaking science in laboratory medicine. , ChirpE Photo Booth ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... N.C., Jan. 5, 2012 Tengion, Inc. (NASDAQ: ... medicine, today announced it has completed the relocation ... to the Company,s existing facility in Winston-Salem, North ... previously announced restructuring, which was designed to fund ...
... SARASOTA, Fla., Jan. 5, 2012  George Miller developed an ... His doctor sent cell scrapings to a pathologist, and ... TMD Limited, a medical tourism company, squamous cell carcinoma ... humans and other animals.  Squamous cell ...
... Jan. 5, 2012  AtheroNova, (OTCQB: AHRO) ("AtheroNova"), a biotech company ... atherosclerotic plaque, announced today that it has appointed Johan M. ... Directors of the Company effective January 3, 2012. Mr. Spoor ... and Medical Committees of the Board. "I ...
Cached Biology Technology:Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 2Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 3Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 4Squamous Cell Cancer Responds to SPDT Therapy 2Squamous Cell Cancer Responds to SPDT Therapy 3Squamous Cell Cancer Responds to SPDT Therapy 4AtheroNova Announces a New Board Member 2AtheroNova Announces a New Board Member 3
(Date:7/23/2014)... HOLE, MA -- What do mollusks, starfish, and ... marine habitat, they are all calcifiersorganisms that use ... skeletons and shells for stability and protection. , ... , published by the Marine Biological Laboratory, addresses ... composition changes worldwide. , As atmospheric carbon dioxide ...
(Date:7/23/2014)... the principal bacteria that cause dental caries, has ... time, possibly coinciding with dietary change linked to ... in a study by researchers from the Universitat ... de Genmica para la Biodiversidad (National Laboratory of ... first time, have sequenced genetic material from this ...
(Date:7/23/2014)... popular culinary herbs oregano and rosemary are packed with ... work in much the same way as prescription anti-diabetic ... ACS, Journal of Agricultural and Food Chemistry , ... a difference, and they also identified which compounds contribute ... de Mejia and colleagues point out that in 2012, ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Ancient genetic material from caries bacterium obtained for the first time 2
... total energy used in the USA is taken up in ... comes from non-renewable energy sources which are in short supply. ... reducing this significant fuel consumption in the US food system ... the Springer journal Human Ecology , David Pimentel and ...
... CO, USA GEOLOGY topics include confirmation that ... a blowout in the Banjar Panji-1 well; evidence of the ... analysis of Yellowstone,s hotspot; and GPS measurements that show why ... GSA Today ,s science article studies the impact of Glen ...
... medicines and the introduction of new anti-arthritis drugs ... (RA), according to guidelines issued by the American ... the University of Alabama at Birmingham (UAB). ... in the UAB Division of Clinical Immunology and ...
Cached Biology News:Why eating less can help the environment 2August 2008 Geology and GSA Today media highlights 2August 2008 Geology and GSA Today media highlights 3August 2008 Geology and GSA Today media highlights 4August 2008 Geology and GSA Today media highlights 5August 2008 Geology and GSA Today media highlights 6August 2008 Geology and GSA Today media highlights 7August 2008 Geology and GSA Today media highlights 8August 2008 Geology and GSA Today media highlights 9August 2008 Geology and GSA Today media highlights 10August 2008 Geology and GSA Today media highlights 11August 2008 Geology and GSA Today media highlights 12New guidelines for treating rheumatoid arthritis 2
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Biology Products: